Richfeel: Have a great hair day
Dr. Apoorva Shah Dr. Sonal Shah, India #39;s leading trichologists and founder of Richfeel Hair and Scalp Clinic, talk about Hair fall Hair prevention. Also, explaining about plant stem-cell...
By: Richfeel Trichology
Read more:
Richfeel: Have a great hair day - Video
Kansas RMC Stem Cell Therapy in the US
In the past, stem cell treatment was only available in Europe. Now, in the US, we are able to provide this potentially life changing treatment to people like...
By: Digital Concierge
Original post:
Kansas RMC Stem Cell Therapy in the US - Video
KYOTO: Prime Minister Narendra Modi Sunday discussed cooperation with Japan to combat sickle cell anaemia that is prevalent in India's tribal regions, an official said.
Modi met Shinya Yamanaka, Japan's stem cell pioneer and 2012 Nobel Prize winner, at Kyoto University and discussed treatment of the disease.
They discussed the "possibilities of sickle cell anaemia cure" and "prospects of cooperation among Indian and Japanese institutes", tweeted an external affairs ministry spokesman.
"The prime minister expressed concern over the prevalence of sickle cell anaemia, especially among tribal communities across India," a statement by the Indian government said.
Sickling decreases the cells' flexibility and results in a risk of various life threatening complications. It mostly occurs in regions where malaria is rampant.
"The prime minister urged Yamanaka to work towards a cure for this," the statement said.
Yamanaka said there were currently no Indian researchers at his institute, the Centre for iPS Cell Research and Application, and "he would like Indian scientists to conduct research at the institute".
Stay updated on the go with The Times of Indias mobile apps. Click here to download it for your device.
Go here to read the rest:
PM Modi meets Nobel prize winner Yamanaka, discusses treatment of sickle cell anaemia remedy
Modi talks with Nobel Laureate Prof Yamanaka about treatment of sickle cell anaemia. Photograph: MEA/Facebook
Japan on Sunday agreed to work with India in developing a treatment for the sickle cell anaemia after Prime Minister Narendra Modi sought help for finding remedy to the deadly disease commonly found among tribals in India.
Modi, who has been keenly looking for a remedy to the disease since his days as the chief minister of Gujarat, discussed the issue with Nobel Prize winner for Medicine (2012) S Yamanaka when he visited the Kyoto University.
The PM, on the second day of his tour, raised the issue during his visit to the stem cell research facility and discussed whether Japan could be of help in this regard. Yamanaka is the director of the university.
"I wanted to understand stem cell research because cultural heritage matters as much to me as scientific heritage. I want to integrate both to make India a developed country. It was a good opportunity for me," Modi said.
The PM discussed the possibility of cooperation in finding a treatment for the disease, said External Affairs Ministry spokesman Syed Akbaruddin.
Sources said the Japanese side said it would work with India in jointly finding the treatment.
The sources said Modi, since his days as the Gujarat CM, has been trying to see if any solution could be found to the disease but has been helpless as no cure has been invented yet.
Sickle cell disease is a serious disorder in which the body makes sickle-shaped red blood cells. "sickle-shaped" means that the red blood cells are shaped like a crescent. Normal red blood cells are disc-shaped and look like doughnuts without holes in the center. They move easily through blood vessels. Red blood cells contain an iron-rich protein called hemoglobin. This protein carries oxygen from the lungs to the rest of the body.
Read more from the original source:
In Japan, Modi discusses sickle cell treatment with Nobel laureate
PUBLIC RELEASE DATE:
29-Aug-2014
Contact: Kris Kitto kris@morethanpr.com 303-320-7790 The Bawmann Group
AURORA, Colo. (Sept. 2, 2014) A team of scientists from the University of Colorado School of Medicine has reported the breakthrough discovery of a process to expand production of stem cells used to treat cancer patients. These findings could have implications that extend beyond cancer, including treatments for inborn immunodeficiency and metabolic conditions and autoimmune diseases.
In an article published Aug. 29 in PLOS ONE, researchers from the Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology and Taiga Biotechnologies, Inc. said they have uncovered the keys to the molecular code that appear to regulate the ability of blood stem cells to reproduce and retain their stem-like characteristics.
The team developed protein products that can be directly administered to blood stem cells to encourage them to multiply without permanent genetic modifications.
"Use of stem cells to treat cancer patients who face bone marrow transplants has been a common practice for four decades," said Yosef Refaeli, Ph.D., an associate dermatology professor and one of the study's lead scientists. "The biggest challenge, however, has been finding adequate supplies of stem cells that help patients fight infection after the procedure."
Gates Stem Cell Center Director Dennis Roop, Ph.D., recognized the magnitude of the team's work.
"Researchers have long attempted to increase the number of blood stem cells in a lab," Roop said. "Most of those approaches have been limited by the nature of the resulting cells or the inadequate number of cells produced."
The technology described in the PLOS ONE article has worked with blood stem cells obtained from cord blood, adult bone marrow or peripheral blood from adults.
More:
CU scientists' discovery could lead to new cancer treatment
Boston, MA (PRWEB) August 29, 2014
A major challenge before new biotechnology start-up companies, especially ones in the biotech start-up dense realm of Boston-Cambridge, is gaining visibility that can lead to important strategic alliances and able investors. James Sherley, the Director of Bostons Adult Stem Cell Technology Center, LLC (ASCTC), has made increasing the local and national visibility of his company an important priority since he started the company in September 2013.
In addition to a social media marketing campaign launched earlier in July of this year, Director Sherley has targeted research and development conferences both nationally and internationally to increase industry awareness of ASCTCs unique portfolio of intellectual property available for licensing and its current commercial development targets. The company is focused on producing two products to address two important needs in drug development and regenerative medicine, respectively, that it is uniquely positioned to address.
ASCTCs most advanced product is an assay that can detect, very early in the drug development pipeline, drug candidates that will ultimately fail because of their toxicity to tissue stem cells. ASCTC developed the new technology in partnership with AlphaSTAR, Corporation, located in Long Beach, California. Currently, such lurking drugs are not detected until after expensive animal testing, more expensive clinical trials, or worse, after marketing. Director Sherley refers to the second product as, A future of pounds and pounds of normal adult tissue stem cells. The company holds a patented technology for mass production of human tissue stem cells. The initial production target is human liver stem cells that can be used to make mature human liver cells for use in drug development and to support liver transplant patients. The company also holds patents for production of pancreatic stem cells and hair follicle stem cells.
The sponsor the 2014 Stem Cells & Regenerative Medicine Conference, in Boston, September 15-16, Terrapinn, Inc., invited ASCTC to attend as a VIP guest. Although ASCTC will not make a formal presentation at this conference, Director Sherley will participate in a roundtable discussion on the topic, Articulating value for up-and-coming regenerative medicine, stem cell and cell-based therapies.
Later in September (22-24), Director Sherley will present one of the selected Next Generation Presentations for new companies at BioPharm America 2014, also taking place in Boston. In addition to the public presentation, ASCTC will also participate in confidential partnering meetings with potential investors and strategic alliance partners arranged by conference organizers.
In October, Director Sherley will present to a primarily academic research audience a more detailed accounting of ASCTCs computer simulation technology for quantifying tissue stem cells in culture. This technology is the basis for the companys new assay for tissue stem cell toxicity. Director Sherley is particularly interested in the response from several experts in tissue stem cell growth dynamics who are invited speakers. The symposium, which will take place at Rhode Island Hospital, a medical affiliate of Brown University in Providence, has the goal of presenting emerging disruptive research in the area of Novel Stem Cells and Vesicles. Director Sherley is a member of the symposium organizing committee. ************************************************************************************************************* The Adult Stem Cell Technology Center, LLC (ASCTC) is a Massachusetts life sciences company established in September 2013. ASCTC Director and founder, James L. Sherley, M.D., Ph.D. is the foremost authority on the unique properties of adult stem cells. The companys patent portfolio contains biotechnologies that solve the two main technical problems production and quantification that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing iPSCs. Currently, ASCTC is employing its technological advantages to pursue commercialization of mass-produced therapeutic human liver cells and facile assays that are early warning systems for drug candidates with catastrophic toxicity due to adverse effects against adult tissue stem cells.
Read the original:
The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences ...
PUBLIC RELEASE DATE:
28-Aug-2014
Contact: Robert Nellis newsbureau@mayo.edu 507-284-5005 Mayo Clinic
ROCHESTER, Minn. A Mayo Clinic researcher and his collaborators have developed an online analytic tool that will speed up and enhance the process of re-engineering cells for biomedical investigation. CellNet is a free-use Internet platform that uses network biology methods to aid stem cell engineering. Details of CellNet and its application to stem cell engineering are described in two back-to-back papers in the journal Cell.
"This free platform has a broad range of uses for all types of cell-based investigations and can potentially offer help to people working on all types of cancer," says Hu Li, Ph.D., investigator in the Mayo Clinic Center for Individualized Medicine and Department of Molecular Pharmacology & Experimental Therapeutics, and co-lead investigator in the two works. "CellNet will indicate how closely an engineered cell resembles the real counterpart and even suggests ways to adjust the engineering."
The network biology platform contains data on a wide range of cells and details on what is known about those cell types. Researchers say the platform can be applied to almost any study and allows users to refine the engineering process. In the long term, it should provide a reliable short cut to the early phases of drug development, individualized cancer therapies, and pharmacogenetics.
CellNet uses 21 cell types and tissues and data from 56 published human and mouse engineering studies as a basis for analyzing and predicting cell fate and corresponding engineering strategies. The platform also offers classification scores to determine differentiation and conversion of induced pluripotent stem cells. It reveals incomplete conversion of engineered microphages and hepatocytes. CellNet can be used for interrogation of cell fate following expression profiling, by classifying input by cell type, quantifying gene regulatory network status, and identifying aberrant regulators affecting the engineering process. All this is valuable in predicting success of engraftment of cancer tumors in mouse avatars for cancer and drug development research. CellNet can be accessed at cellnet.hms.harvard.edu.
###
Co-lead authors with Dr. Li are Patrick Cahan, Ph.D., and Samantha Morris, Ph.D., of Boston Children's Hospital. The senior investigators are George Q. Daley, M.D., Ph.D., Director of the Stem Cell Transplantation Program at Boston Children's and senior investigator on both studies and James Collins, Ph.D., Core Faculty member at the Wyss Institute and the William F. Warren Distinguished Professor at Boston University, co-senior investigator on one of the studies.
Investigators are supported in part by the National Institutes of Health, specifically, the National Institute of Diabetes and Digestive and Kidney Diseases and the National Heart, Lung, and Blood Institute; the Children's Hospital Stem Cell Program; the Howard Hughes Medical Institute; Alex's Lemonade Stand Foundation; the Ellison Medical Foundation; the Doris Duke Medical Foundation; the Mayo Clinic Center for Individualized Medicine and the Mayo Clinic Center for Regenerative Medicine.
Go here to see the original:
New tool aids stem cell engineering for medical research
Boy Scout Troop 286 Icebucket Challenge for the Scoutmaster
Ice Bucket Challenge Completed! With a whole lot of help from my Scouts! Donation went to the Midwest Stem Cell Therapy Center at KU Med in Kansas City. They do some terrific work there and...
By: Scott Medlock
Continued here:
Boy Scout Troop 286 Icebucket Challenge for the Scoutmaster - Video
By Dow Jones Business News, August 27, 2014, 12:55:00 AM EDT
TOKYO--A scandal that started with a few suspicious images has led Japan's most prestigious research institute to slash its stem-cell unit by half and acknowledge deeper flaws in its ethics.
The move by the Riken institute came seven months after the publication of papers that it initially hailed as equal in importance to the Copernican revolution in astronomy. Since then, the papers have been retracted, and one of the co- authors committed suicide.
On Wednesday, Riken said it would scale down to half its size the Center for Developmental Biology, rename the center and choose a new director with input from non-Japanese scientists, an indication of how the scandal has damaged the reputation of Japanese science.
"We believe it is important to move forward with the restructuring to improve the quality and promote honest research," said Ryoji Noyori, the Nobel Prize winner who leads Riken.
Riken's overhaul could also sway the field of stem-cell science, which has received billions of dollars in research funds in the hopes of cures for ailments such as diabetes and heart disease.
Some details of the overhaul, including whether anyone beside the director would indeed lose their job, remained murky. Nevertheless, science writer Shinya Midori said, "This could trigger scaling down in the field of regenerative medicine."
The scandal at Riken has deeply shaken the country's science establishment and the wider stem-cell world and sparked a debate about research ethics in Japan amid "results-first" pressure.
The drama has focused on the institute's 14-year-old developmental-biology center and erupted after one of its scientists, Haruko Obokata, was found guilty of manipulating data in a pair of papers published in the journal Nature. The studies, which claimed to show a groundbreaking method of making stem cells by dipping cells in a mild acid solution, were quickly challenged and Nature retracted the papers in July, saying they contained inaccurate data.
Riken initially stood by the 31-year-old Dr. Obokata, who had been hailed as a national hero after her research was first published, but later distanced itself from what it called her "sloppy data management" and poor research ethics.
Go here to read the rest:
Japan's Riken Reboots After Stem-Cell Scandal
Stem cell technology pioneer,DefiniGEN Ltdhas joined the Pfizer-inspired European Bank for induced pluripotent stem cells (EBiSC) consortium.
The consortium comprises 26 partners, and has been newly-formed with support from the Innovative Medicines Initiative (IMI) and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
DefiniGen, a Cambridge University spin-out that has raised millions, represents one of the first commercial opportunities to arise from the universitys expertise in stem cells and is based on the research of Dr Ludovic Vallier, Dr Tamir Rashid and Professor Roger Pedersen of the universitys Anne McLaren Laboratory of Regenerative Medicine.
The EBiSC iPS cell bank will act as a central storage and distribution facility for human iPS cells, to be used by researchers across academia and industry in the study of disease and the development of new therapeutics. DefiniGENs role will be to validate EBiSC iPS cell lines by generating liver hepatocyte cells for toxicology, disease modelling, and regenerative medicine applications.
Dr Marcus Yeo, CEO of DefiniGEN, said: We are delighted to be a part of this ground-breaking consortium which will provide a crucial platform resource to enable the realisation of the full potential of iPS technology.
Conceptualised and coordinated by Pfizer Ltd in Cambridge, UK and managed by Roslin Cells Ltd in Edinburgh, the EBiSC bank aims to become the European go to resource for high quality research grade human iPS cells.
Today, iPS cells are being created in an increasing number of research programmes underway in Europe, but are not being systematically catalogued and distributed at the necessary scale to keep pace with their generation, nor to meet future demand.
The 35 million project will support the initial build of a robust, reliable supply chain from the generation of customised cell lines, the specification to internationally accepted quality criteria and their distribution to any global qualified user, ensuring accessibility to consistent, high quality tools for new medicines development.
Ruth McKernan, CSO of Pfizers Neusentis research unit in Cambridge, said: We are excited to be a part of this precompetitive collaboration to build a sustainable repository of high quality human iPS cell lines.
For many areas of research in academia and in industry, understanding the biological basis of disease heterogeneity is the next horizon. A bank of well-characterised iPS lines with strong relevance to the entire research community will help us all in our mission to bring therapies to patients.
View post:
Pfizer buys into Cambridge life science innovation